<DOC>
	<DOCNO>NCT01336231</DOCNO>
	<brief_summary>Longitudinal study nonrandomized , multicenter observational descriptive monitoring patient treat anti-angiogenic metastatic kidney cancer</brief_summary>
	<brief_title>Impact Quality Life , Fatigue Cognitive Function Anti-angiogenesis Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Patient ( e ) Age ( e ) 18 year Kidney cancer metastatic locally advanced Antiangiogenic target therapy ( bevacizumab , sorafenib , sunitinib , temsirolimus , another molecule develop obtain authorization indication ) may associate interferon combine together Proposed treatment first line second line Brain imaging find brain metastasis Having sign informed consent study participation The patient may receive prior antiangiogenic Cancer kidney primitive Previous history cancer kidney cancer complete remission le 5 year Patients 18 year Patients whose treatment associate chemotherapy disorder cognitive function exist treatment delivery Pathology psychiatric evolutionary Refusal participation Patient unable respond cognitive test Drug use Heavy drinking ( WHO criteria ) History stroke History head trauma Brain metastases known MMS normal compare existing standard age sociocultural</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>quality life</keyword>
	<keyword>cognitive function</keyword>
	<keyword>antiangiogenic agent</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>metastatic</keyword>
</DOC>